<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM IMMULOGIC
PHARMACEUTICAL CORPORATION CONSOLIDATED STATEMENT OF NET ASSETS AS OF SEPTEMBER
30, 2000 AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH IMMULOGIC
PHARMACEUTICAL CORPORATION FORM 10-Q FOR THE PERIOD ENDING SEPTEMBER 30, 2000.
</LEGEND>
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-2000
<PERIOD-START>                             JAN-01-2000
<PERIOD-END>                               SEP-30-2000
<CASH>                                           1,770
<SECURITIES>                                     1,091
<RECEIVABLES>                                        0
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                                 6,846
<PP&E>                                               0
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                                   6,846
<CURRENT-LIABILITIES>                              904
<BONDS>                                              0
                                0
                                          0
<COMMON>                                             0
<OTHER-SE>                                       5,942
<TOTAL-LIABILITY-AND-EQUITY>                     6,846
<SALES>                                              0
<TOTAL-REVENUES>                                     0
<CGS>                                                0
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                                      0
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                         0
<EPS-BASIC>                                          0
<EPS-DILUTED>                                        0<F1>
<FN>
<F1>IMMULOGIC PHARMACEUTICAL CORPORATION "THE COMPANY" IS ADOPTED THE LIQUIDATION
BASIS OF ACCOUNTING AS OF JULY 1, 1999.
</FN>


</TABLE>



© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission